EBMT Annual Meeting

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.

An ongoing trial could establish new standard of care for chronic graft-vs-host disease.

Amandeep Salhotra, MD, discusses a retrospective observational analysis comparing Orca-T to standard graft with posttransplant cyclophosphamide.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

Adding itacitinib to posttransplant cyclophosphamide and tacrolimus proved safe and well tolerated, with low GVHD rates and no nonrelapse mortality.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.